Hu Junyi, Zhou Lijie, Song Zhengshuai, Xiong Ming, Zhang Youpeng, Yang Yu, Chen Ke, Chen Zhaohui
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
J Cell Physiol. 2019 Sep;234(9):15607-15618. doi: 10.1002/jcp.28208. Epub 2019 Feb 18.
Bladder cancer (BC) is one of the most common neoplastic diseases worldwide. With the highest recurrence rate among all cancers, treatment of BC only improved a little in the last 30 years. Available biomarkers are not sensitive enough for the diagnosis of BC, whereas the standard diagnostic method, cystoscopy, is an invasive test and expensive. Hence, seeking new biomarkers of BC is urgent and challenging. With that order, we screened the overlapped differentially expressed genes (DEGs) of GSE13507 and TCGA BLCA datasets. Subsequent protein-protein interactions network analysis recognized the hub genes among these DEGs. Further functional analysis including Gene Ontology and KEGG pathway analysis and gene set enrichment analysis were processed to investigate the role of these genes and potential underlying mechanisms in BC. Kaplan-Meier analysis and Cox hazard ratio analysis were carried out to clarify the diagnostic and prognostic role of these genes. In conclusion, our present study demonstrated that ACTA2, CDC20, MYH11, TGFB3, TPM1, VIM, and DCN are all potential diagnostic biomarkers for BC. And may also be potential treatment targets for clinical implication in the future.
膀胱癌（BC）是全球最常见的肿瘤性疾病之一。在所有癌症中复发率最高，过去30年里膀胱癌的治疗进展甚微。现有的生物标志物对膀胱癌的诊断不够敏感，而标准诊断方法膀胱镜检查是一种侵入性检查且费用高昂。因此，寻找新的膀胱癌生物标志物既紧迫又具有挑战性。基于此，我们筛选了GSE13507和TCGA BLCA数据集的重叠差异表达基因（DEG）。随后的蛋白质-蛋白质相互作用网络分析识别出了这些DEG中的核心基因。进一步进行了包括基因本体论和KEGG通路分析以及基因集富集分析在内的功能分析，以研究这些基因在膀胱癌中的作用及潜在的机制。进行了Kaplan-Meier分析和Cox风险比分析，以阐明这些基因的诊断和预后作用。总之，我们目前的研究表明，ACTA2、CDC20、MYH11、TGFB3、TPM1、VIM和DCN都是膀胱癌潜在的诊断生物标志物，并且未来可能也是临床应用中的潜在治疗靶点。
